214 related articles for article (PubMed ID: 35609512)
1. Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Schöffski P
Oncol Res Treat; 2022; 45(9):525-543. PubMed ID: 35609512
[TBL] [Abstract][Full Text] [Related]
2. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
3. Managing Liposarcomas: Cutting Through the Fat.
Manji GA; Schwartz GK
J Oncol Pract; 2016 Mar; 12(3):221-7. PubMed ID: 26962163
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.
Suarez-Kelly LP; Baldi GG; Gronchi A
Expert Opin Pharmacother; 2019 Aug; 20(12):1503-1515. PubMed ID: 31136210
[No Abstract] [Full Text] [Related]
5. Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center.
Langmans C; Cornillie J; van Cann T; Wozniak A; Hompes D; Sciot R; Debiec-Rychter M; Vandenbempt I; Schöffski P
Oncol Res Treat; 2019; 42(7-8):396-404. PubMed ID: 31170709
[TBL] [Abstract][Full Text] [Related]
6. Current management options for liposarcoma and challenges for the future.
Kollár A; Benson C
Expert Rev Anticancer Ther; 2014 Mar; 14(3):297-306. PubMed ID: 24397249
[TBL] [Abstract][Full Text] [Related]
7. Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.
Assi T; Ngo C; Faron M; Verret B; Lévy A; Honoré C; Hénon C; Le Péchoux C; Bahleda R; Le Cesne A
Curr Treat Options Oncol; 2023 Nov; 24(11):1598-1613. PubMed ID: 37843627
[TBL] [Abstract][Full Text] [Related]
8. [Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Italiano A; Toulmonde M; Bui-Nguyen B
Bull Cancer; 2010 Jun; 97(6):679-86. PubMed ID: 20483708
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the understanding and management of liposarcoma.
Haddox CL; Riedel RF
Fac Rev; 2021; 10():1. PubMed ID: 33659920
[TBL] [Abstract][Full Text] [Related]
10. Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma.
McGovern Y; Zhou CD; Jones RL
Front Oncol; 2017; 7():292. PubMed ID: 29250486
[TBL] [Abstract][Full Text] [Related]
11. Application of molecular biology to individualize therapy for patients with liposarcoma.
Abbas Manji G; Singer S; Koff A; Schwartz GK
Am Soc Clin Oncol Educ Book; 2015; ():213-8. PubMed ID: 25993159
[TBL] [Abstract][Full Text] [Related]
12. The importance of treating by histological subtype in advanced soft tissue sarcoma.
Martín Broto J; Le Cesne A; Reichardt P
Future Oncol; 2017 Jan; 13(1s):23-31. PubMed ID: 27918201
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Keung EZ; Lazar AJ; Torres KE; Wang WL; Cormier JN; Ashleigh Guadagnolo B; Bishop AJ; Lin H; Hunt KK; Bird J; Lewis VO; Patel SR; Wargo JA; Somaiah N; Roland CL
BMC Cancer; 2018 Sep; 18(1):913. PubMed ID: 30249211
[TBL] [Abstract][Full Text] [Related]
14. First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.
Stacchiotti S; Van der Graaf WTA; Sanfilippo RG; Marreaud SI; Van Houdt WJ; Judson IR; Gronchi A; Gelderblom H; Litiere S; Kasper B
Cancer; 2022 Aug; 128(15):2932-2938. PubMed ID: 35561319
[TBL] [Abstract][Full Text] [Related]
15. [Histology-Specific Chemotherapy in Soft-Tissue Sarcomas].
Kobayashi E; Kawai A
Gan To Kagaku Ryoho; 2017 Jun; 44(6):468-472. PubMed ID: 28698435
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality?
Blay JY
Future Oncol; 2019 Sep; 15(26s):5-10. PubMed ID: 31500446
[TBL] [Abstract][Full Text] [Related]
17. Myxoid Liposarcomas: Systemic Treatment Options.
Nassif EF; Keung EZ; Thirasastr P; Somaiah N
Curr Treat Options Oncol; 2023 Apr; 24(4):274-291. PubMed ID: 36853469
[TBL] [Abstract][Full Text] [Related]
18. Dedifferentiated Liposarcoma: Systemic Therapy Options.
Gahvari Z; Parkes A
Curr Treat Options Oncol; 2020 Feb; 21(2):15. PubMed ID: 32026050
[TBL] [Abstract][Full Text] [Related]
19. Lipomatous tumors.
Weiss SW
Monogr Pathol; 1996; 38():207-39. PubMed ID: 8744279
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy for liposarcoma: current and emerging synthetic treatments.
Chamberlain F; Benson C; Thway K; Huang P; Jones RL; Gennatas S
Future Oncol; 2021 Jul; 17(20):2659-2670. PubMed ID: 33880964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]